Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 21;28(23):3963-71.
doi: 10.1016/j.vaccine.2010.03.046. Epub 2010 Apr 9.

Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains

Rachmat Hidajat  1 , Seraphin Kuate, David Venzon, Vaniambadi Kalyanaraman, Irene Kalisz, James Treece, Ying Lian, Susan W Barnett, Marjorie Robert-Guroff
Affiliations

Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains

Rachmat Hidajat et al. Vaccine. .

Abstract

An HIV Env immunogen capable of eliciting broad immunity is critical for a successful vaccine. We constructed and characterized adenovirus 5 host range mutant (Ad5hr) recombinants encoding HIV(SF162) gp160 (subtype B) and HIV(TV1) gp160 (subtype C). Immunization of mice with one or both induced cellular immunity to subtype B and C peptides by ELISpot, and antibody responses with high binding titers to HIV Env of subtypes A, B, C, and E. Notably, Ad5hr-HIV(TV1) gp160 induced better cellular immunity than Ad5hr-HIV(SF162) gp160, either alone or following co-administration. Thus, the TV1 Env recombinant alone may be sufficient for eliciting immune responses against both subtype B and C envelopes. Further studies of Ad5hr-HIV(TV1) gp160 in rhesus macaques will evaluate the suitability of this insert for a future phase I clinical trial using a replication-competent Ad4 vector.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Construction of Ad5hr HIV-1 gp160 recombinants
(A) Western blot of QBI 293 cell lysate after being transfected with plasmid expressing HIVTV1 gp160 (lane 2) or HIVSF162 gp160 (lane 3). The Env band was not observed in mock transfected cells (lane 1) or untransfected cells (lane 4). (B) Schematic diagram of the Ad5hr-shuttle plasmid and the left hand Ad5hr fragment used to create replication-competent Ad5hr-recombinant virus by homologous recombination. (C) Expression of HIV-1 gp160 in QBI 293 cells after being transduced with 1 MOI of Ad5hr-HIVTV1 (lane 1) or Ad5hr-HIVSF162 (lane 2).
Figure 2
Figure 2. HIV-1 gp160 specific ELISpot responses following immunization with Ad5hr recombinants
Spleen cells of immunized mice were harvested at the indicated time points and tested for IFN-γ secretion after stimulation with the indicated HIV-1 gp160 peptides. Significant differences in comparison to the baseline control are indicated as follows: a, p <0.01; b, p <0.02; c, p <0.03; d, p < 0.04; e, p <0.05.
Figure 3
Figure 3. Mean vaccine-induced IFN-γ-secreting cells by immunization group
SFC are plotted as a function of time post-immunization, in response to the indicated Env peptide stimuli. Mean values and standard errors of the mean are shown.
Figure 4
Figure 4. Anti-HIV Env binding antibody in immunized mouse sera
Sera collected from immunized mice in each group at indicated time points were pooled and tested for specific binding to HIV Env proteins of several different HIV-1 subtypes. Results are the average of 2 independent measurements of 450nm absorbance at serum dilutions of 1:50.
Figure 5
Figure 5. Antibody binding titers against HIV Env proteins of different subtypes
Results of sera pooled according to immunization group and time post-immunization. Means of each HIV-Env subtype are shown.
See this image and copyright information in PMC

References

    1. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520–9. - PMC - PubMed
    1. Haase AT. The pathogenesis of sexual mucosal transmission and early stages of infection: obstacles and a narrow window of opportunity for prevention. AIDS. 2001;15(Suppl 1):S10–1. - PubMed
    1. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol. 2006;80(12):6177–81. - PMC - PubMed
    1. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006;80(18):9217–25. - PMC - PubMed
    1. Miller CJ, Genescà M, Abel K, Montefiori D, Forthal D, Bost K, et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol. 2007;81(10):5024–35. - PMC - PubMed

Publication types

Substances